Publications

Life Saving Drugs Program – Avalglucosidase alfa (Nexviazyme®) outcome statement

Summary of the consideration of the application from Sanofi Pty Ltd for the inclusion of avalglucosidase alfa (Nexviazyme®) on the Life Saving Drugs Program (LSDP) for the treatment of Pompe Disease.

Downloads

Life Saving Drugs Program – Avalglucosidase alfa (Nexviazyme®) outcome statement

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
Fact sheet
Audience:
General public
Language:
English
Tags: 

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.